Revolutionizing Rare Disease Treatment: Introducing Soligenix's Breakthrough HyBryte™

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit https://www.redchip.com/stocks/SNGX/ to learn more.

Transcription:

Soligenix opens enrollment of expanded clinical trial of HyBryte in cutaneous T-cell lymphoma, building on the successful Phase 3 study. Discussions with FDA on design of a confirmatory Phase 3 study of HyBryte are underway. Learn more at SNGXinfo.com.